System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42273944 DOI: 10.3324/haematol.2026.300853

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica

Authors: Robert Stuver, Zachary R Moore, Stefan K Barta, Rahul S Bhansali, Ruth Choa, Zachary D Epstein-Peterson, Nivetha Ganesan, Paola Ghione, Salvia Jain, Eric Jacobsen, William T Johnson, Joe D Lukowski, Matthew Lunning, Sean McCabe, Mwanasha Merrill, Alison J Moskowitz, Shambhavi Singh, Eleanor Taranto, Joachim Yahalom, Kerry J Savage, Brandon S Imber, Steven M Horwitz

Affiliations

  • Memorial Sloan Kettering Cancer Center, New York.
  • Memorial Sloan Kettering Cancer Center, New York.
  • Hospital of the University of Pennsylvania, Philadelphia.
  • Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Dana-Farber Cancer Institute, Boston, Massachusetts.
  • University of Nebraska Medical Center, Omaha, Nebraska.
  • Weill Cornell Medicine, New York.
  • University of California San Francisco, San Francisco.
  • Duke Cancer Center, Durham.
  • Center for Lymphoid Cancer, BC Cancer and the University of British Columbia.

Abstract

Peripheral T-cell lymphomas are rare, generally aggressive lymphomas. Early stage disease represents a minority, and current treatment guidelines generally do not distinguish by stage or do so based on limited evidence. In order to understand practices and outcomes in this setting, we evaluated a multicenter cohort of patients with early stage nodal T-cell lymphomas (peripheral Tcell lymphoma, not otherwise specified [PTLC-NOS], nodal T-follicular helper cell lymphoma [TFHL], and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma [ALK-negative ALCL]) from 2001 to 2022. We evaluated differences in outcomes by stage, histology, and treatment strategy, including consolidation after chemotherapy, which often includes radiation therapy (RT) and sometimes includes autologous stem cell transplant (ASCT). In total, we identified 132 patients. All patients received chemotherapy, 78 (59%) received chemotherapy plus RT, and 18 (14%) received ASCT. For the entire cohort, five-year progression-free (PFS) and overall survival (OS) was 56% and 68%. Outcomes were particularly encouraging in stage I disease, with five-year PFS and OS of 66% and 79%. Among patients with stage I disease responding to chemotherapy, patients treated with chemoradiation had especially favorable outcomes (five-year PFS: 70%, OS: 86%). Among patients with stage II disease responding to chemotherapy, outcomes were inferior to those with stage I disease and were similar regardless of treatment strategy. These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.

MeSH

Cells, Hematology, Lymphoma, Drug Therapy, Histology, Therapeutics, Lymphoma, T-Cell, Peripheral, T-Lymphocytes, Lymphoma, T-Cell, Chemotherapy